Table 2.

Results of base case and one-way sensitivity analyses

Parameter	Cost (2015 USD)		ΔC	Effectiveness (QALYs)		ΔE	ICER (USD/QALY gained)	NHBa (QALYs)	NMBa (2015 USD)
	Conventional	Raloxifene		Conventional	Raloxifene
Base case	5,114	5,336	221	8.7306	8.7366	0.0060	36,891	−0.0051	−101.34
Discount rate: 0	7,091	7,368	277	10.9581	10.9672	0.0091	30,445	−0.0048	−95.05
Discount rate: 0.05	4,255	4,448	193	7.6814	7.6860	0.0046	42,005	−0.0051	−101.22
No residual effects after medication discontinuation	5,114	5,336	221	8.7139	8.7179	0.0040	55,336	−0.0071	−141.34
0.8 times raloxifene efficacy	5,114	5,336	221	8.7306	8.7302	−0.0004	−553,360	−0.0115	−229.34
1.2 times raloxifene efficacy	5,114	5,336	221	8.7306	8.7472	0.0166	13,334	0.0055	110.66
0.8 times raloxifene persistence	5,114	5,171	57	8.7202	8.7203	0.0001	565,640	−0.0027	−54.56
1.2 times raloxifene persistence	5,114	5,567	453	8.7565	8.7724	0.0159	28,476	−0.0067	−134.76
0.8 times raloxifene adherence	5,114	5,326	211	8.7306	8.7315	0.0009	234,851	−0.0097	−193.37
1.2 times raloxifene adherence	5,114	5,346	231	8.7306	8.7426	0.0120	19,268	0.0004	8.79
Treatment duration: 2 years	4,926	4,958	32	8.7306	8.7361	0.0055	5,805	0.0039	78.07
Treatment duration: 10 years	4,926	4,958	32	8.7306	8.7373	0.0067	4,765	0.0051	102.07
0.8 times annual fracture rates	4,157	4,343	186	9.0458	9.0497	0.0039	47,677	−0.0054	−107.94
1.2 times annual fracture rates	6,051	6,309	258	8.4288	8.4365	0.0077	33,452	−0.0052	−103.58
0.8 times fracture inpatient costs	4,286	4,512	226	8.7306	8.7366	0.0060	37,730	−0.0053	−106.38
1.2 times fracture inpatient costs	5,943	6,159	216	8.7306	8.7366	0.0060	36,051	−0.0048	−96.31
0.8 times nursing home costs	4,972	5,192	221	8.7306	8.7366	0.0060	36,756	−0.0050	−100.54
1.2 times nursing home costs	5,257	5,479	222	8.7306	8.7366	0.0060	37,025	−0.0051	−102.15
0.8 times annual raloxifene costs	5,114	5,235	121	8.7306	8.7366	0.0060	20,193	−0.0001	−1.16
1.2 times annual raloxifene costs	5,114	5,436	322	8.7306	8.7366	0.0060	53,588	−0.0101	−201.53
0.8 times base case HSUV	5,114	5,336	221	6.8554	6.8607	0.0053	41,763	−0.0058	−115.34
1.2 times base case HSUV	5,114	5,336	221	10.6890	10.6953	0.0063	35,134	−0.0048	−95.34
Initial population age: 70 years	4,514	4,686	173	7.1923	7.1981	0.0058	29,768	−0.0028	−56.65
Initial population age: 75 years	3,870	4,006	136	5.6785	5.6832	0.0047	28,958	−0.0021	−42.10
Initial population age: 80 years	3,159	3,272	113	4.3061	4.3110	0.0049	23,084	−0.0008	−15.11

Note:

^aWillingness-to-pay threshold is set at USD 20,000 per QALY gained.

Abbreviations: USD, United States Dollars; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; ΔC, incremental costs; ΔE, incremental effectiveness; NHB, net health benefit; NMB, net monetary benefit; HSUV, health-state utility value.